Home › Amblyopia › NCT06712849
Noninvasive Brain Stimulation in Adult Amblyopia
Multi-day Effect of Noninvasive Brain Stimulation in Adults With Amblyopia
Who can join
Ages 18 to 55 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Adults between 18 and 55 years of age * Formal diagnosis of amblyopia in one or both eyes of any etiology Exclusion Criteria: * History of optic nerve disease, including glaucoma and optic neuritis * History of neurological conditions, including demyelinating disease or stroke * Presence of metal or electronic implants in or on the body, including pacemakers * Taking medications that can affect normal neurological function, including antipsychotics, antiepileptics, and opioids
About the study
The goal of this randomized controlled trial is to investigate the effectiveness of non-invasive brain stimulation in treating adults with amblyopia. The main questions it aims to answer are:
1. What are the effects of non-invasive brain stimulation on neuronal plasticity in the visual cortex of adults with amblyopia, and does it produce lasting changes? 2. Do cumulative sessions of non-invasive brain stimulation influence neural plasticity and higher-order visual functions in adults with amblyopia?
The investigators hypothesize that non-invasive brain stimulation will show a positive cumulative effect after five (5) consecutive days of stimulation on visual perception and function in adults with amblyopia.
Participants will be randomized into one of two treatment groups:
1. High-frequency transcranial random noise stimulation (hf-tRNS). 2. Sham stimulation.
Researchers will compare baseline measurements of crowded visual acuity, contrast sensitivity, stereoacuity, phosphene thresholds, global motion perception, form pattern recognition and pattern-reversal visual evoked potentials (VEPs) to post-treatment measurements for each group.
What is being tested
- Sham Transcranial Random Noise Stimulation (device)
- High Frequency Transcranial Random Noise Stimulation (device)
Sponsor: Midwestern University · Participants: 60 · Started: May 1, 2024
Contact the study team
- Arijit Chakraborty, PhD · Phone: 630-960-3172
- Adrienne C Quan, OD · Phone: 630-960-3183
Official record on ClinicalTrials.gov — NCT06712849
Locations in the U.S.
| Illinois | Midwestern University Eye Institute, Downers Grove |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.